November 25, 2021
Article
Analysis documents 9% rise in shots distributed after federal officials pushed for vaccination.
November 24, 2021
The FDA has approved patients 6 months and older to receive Seqirus's first-ever adjuvanted, cell-based influenza vaccine.
November 17, 2021
The National Academy of Medicine released 4 reports with COVID-19-influenced recommendations to prepare and respond to an influenza pandemic.
November 05, 2021
Interim, unpublished data show PAXLOVID is associated with 89% reductions in risk of COVID-19 hospitalization or death. Pfizer is now seeking FDA emergency authorization.
November 04, 2021
The Biden administration is also setting mandates for health care workers in facilities receiving federal aid.
The investigational oral antiviral therapy from Merck is still awaiting FDA authorization.
October 29, 2021
The Walmart-distributed Better Homes & Gardens aromatherapy spray “Lavender & Chamomile with Gemstones” was identified as causing melioidosis in 4 individuals, 2 of whom died.
October 21, 2021
The FDA and CDC have authorized and recommended 3 different booster doses, to be used in "mix-and-match" strategy among eligible adults. What does this mean for immunity?
The National Foundation for Infectious Diseases (NFID) recently sponsored a media briefing addressing the risks of contracting influenza and pneumococcal disease in the midst of a still-flourishing COVID-19 pandemic.
October 19, 2021
Infants, children, and adolescents can carry and spread COVID-19 at the same rate as adults.
